Abstract: The aim of this study is to propose a scoring system to determine the activity of the eyes, and to evaluate our medications in the treatment of ocular inflammation and vasculitis in Behect's disease (BD). Eleven activity and 5 chronicity (constant) parameters are scored from zero to 4 to consider the condition of each eye in Oculo-Behcet's disease. Both parameters are considered in our therapeutic scoring. The activity variables are: Episcleritis and/or ...
Abstract: Introduction: There are several reports of good effects of Cyclosporine A (CsA) in the treatment of Behcet's disease (BD). We studied the long term effect of CsA in prospective open clinical trial on posterior uveitis (PU) and retinal vasculitis (RV) of BD. Materials & Methods: Twenty three patients with PU and/or RV diagnosed as BD (according to the Iran and to the Japan criteria) were selected. Initially CsA 5 mg/Kg/day orally ...
Abstract: Introduction: there are several reports of good effects of Cyclosporine A (Cs A) in the treatment of Behcet's disease (BD). We studied the long term effect, of A Cs A in a prospective open clinical trial on posterior uveitis (PU) and retinal vasculitis (RV) of BD. Materials & Methods: Twenty three patients with PU and / or RV diagnose as BD (according to the Iran and to the Japan criteria) ...
Abstract: The outcome of ocular manifestations of Behcet’s Disease remains uncertain and unpredictable despite cytotxic drugs. One of our recent studies, presented to the 1995 Korean Rheumatology Annual Meeting, showed that one third of patients were None Responders, regardless of what treatment used. This study was designed to search for factors predicting the final outcome at the beginning of the treatment. Patients having more than one year of treatment were selected ...
Abstract: Behcet’s Unite, Shariati Hospital the aim to propose a scoring system for the treatment of the ocular inflammation one vasculitis by our medications and to evaluate the state of the activity of the eye. Eleven activity and five chronicity (constant) parameters are scored from zero to four to consider the condition of each eye. The activity variables are: episcleritis &/or scleritis, anterior uveitis, hyalites, IMU, central periphlebitis &/or thrombosis, central periartertis, peripheral ...
Abstract: Introduction: Opthalmologic manifestations are the major cause of morbidity in Behcet’s Disease. If not treated, they usually progress toward sever loss of vision or blindness. Cytotoxic drugs are the main therapeutic agents. Materials & Methods: In an open, non randomized, control study, pulse cyclophosphamide (PCP), low dose pulse cyclophosphamide (LDP), weakly methtrexate (MTX), chlorambucil (CHL), oral cyclophosphamide (OCP), and cyclosporine A (CYA) were used in a standard protocol for 778 patients. ...
Abstract: Porpose: To determine the risk factors in the prognosis and the visual outcome of the disease. Methods: This is a retrospective study of 361 patients, having Behcet’s disease and treated by immunosuppressives and steroids, followed-up at Shariatti Hospital (mean duration of follow-up was 2.27 years). The ocular examinations at the first and last visit are recorded and compared. Results: Vision ...
Abstract: Pulse cyclophosphamide (PCP) is the most effective and the least toxic treatment in posterior uveitis (pU) and/or retinal vasculitis (RV) of Behcet's disease (BD). Conventional doses (1 g/m2) may be associated with minor side effects such as hair loss, nausea and vomiting. To find whether lower doses, such as those already employed in Lupus nephritis should be useful, we administered IVLDP (0.5 g/m2/month) plus prednisolone (0.5 mg/kg/day) to 40 BD ...
Abstract: It is accepted today that cytotoxic drugs are the only remittent agents in posterior uveitis (PU) and retinal vasculitis (RV) of Behcet's disease (BD). The important question is which cytotoxic is the most effective and the least harmful. We compare here the results of 3 efficient methods of cytotoxic therapy with the same mean follow-up time of 12 months: I.V. Pulse Cyclophosphamide (PCP) in 121 patients, weekly low dose Methotrexate ...
Abstract: Antimalarials are among the most important disease modifying drugs used in Rheumatology. The major problem with them is their effects on eyes. We have done a retrospective study on 1598 patients with RA and SLE using Chloroquine for 1 month to 16 years (Mean 41 months). Eye problems was detected in 330 patients (20.6%). We found corneal deposition in 205 (13%) that was graded as severe (11%), moderate (12%) and ...